BioSpace News Archive

Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, Inc. today announced a collaboration agreement in AI for new drug design.

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company will participate at Småbolagsdagarna in Stockholm, Sweden, on June 13 at 14:20 CET.

Zerion Pharma A/S announces the publication of joint experimental work on its Dispersome® technology in the International Journal of Pharmaceutics and Pharmaceutical Research, two peer-reviewed papers.

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has accepted for review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.

LianBio today announced the completion of enrollment in the Phase 3 LIBRA clinical trial of TP-03 in Chinese patients with Demodex blepharitis.

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2023 on Thursday, July 27, 2023.

Syros Pharmaceuticals today announced that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the Sidoti June 2023 Virtual Small-Cap Conference. Management will also be available for one-on-one meetings.

Astellas Pharma Inc., and Kate Therapeutics announced an exclusive license agreement to develop and commercialize KT430.

Kate Therapeutics Inc., a next-generation gene therapy company, emerged from stealth mode with a $51 million Series A financing co-led by founding investor Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures.

Lotus Clinical Research announced it has entered into a strategic partnership with Trialogics to strengthen their existing relationship and expand Lotus’ use of Trialogics’ clinical trial software offerings.